Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

Signed informed consent
≥ 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ and bone marrow function
Has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Have advanced (metastatic/unresectable) cancers in one of the following:

Histologically or cytologically confirmed urothelial cancer
Histologically or cytologically confirmed large cell neuroendocrine tumor of lung
Histologically or cytologically confirmed homologous recombination deficient (HRD) positive endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation
Adequate contraceptive precautions

Exclusion Criteria:

Known symptomatic central nervous system (CNS) metastasis requiring steroids
History of prior malignancy within 2 years of enrollment
Clinically significant cardiovascular disease
Active infection requiring systemic therapy
Significant non-neoplastic liver disease
Prior treatment with trabectedin or lurbinectedin
Treatment with an investigational agent within 4 weeks of enrollment
Received live vaccine with 4 weeks of first dose
Prior allogeneic bone marrow or solid organ transplant
Positive hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening
Positive human immunodeficiency virus (HIV) infection at screening